Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2

doi:10.1126/science.abi4708

GSTDTAP > 气候变化

DOI	10.1126/science.abi4708
	Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
	Tia A. Tummino; Veronica V. Rezelj; Benoit Fischer; Audrey Fischer; Matthew J. O’Meara; Blandine Monel; Thomas Vallet; Kris M. White; Ziyang Zhang; Assaf Alon; Heiko Schadt; Henry R. O’Donnell; Jiankun Lyu; Romel Rosales; Briana L. McGovern; Raveen Rathnasinghe; Sonia Jangra; Michael Schotsaert; Jean-René Galarneau; Nevan J. Krogan; Laszlo Urban; Kevan M. Shokat; Andrew C. Kruse; Adolfo García-Sastre; Olivier Schwartz; Francesca Moretti; Marco Vignuzzi; Francois Pognan; Brian K. Shoichet
	2021-07-30
发表期刊	Science
出版年	2021
英文摘要	In the battle against COVID-19, drugs discovered in repurposing screens are of particular interest because these could be rapidly implemented as treatments. However, Tummino et al. deliver a cautionary tale, finding that many leads from such screens have an antiviral effect in cells through phospholipidosis, a phospholipid storage disorder that can be induced by cationic amphiphilic drugs (see the Perspective by Edwards and Hartung). There is a strong correlation between drug-induced phospholipidosis and inhibition of severe acute respiratory syndrome coronavirus 2 replication in cells. Unfortunately, drugs that have an antiviral effect in cells through phospholipidosis are unlikely to be effective in vivo. Screening out such drugs may allow a focus on drugs with better clinical potential. Science , abi4708, this issue p. [541][1]; see also abj9488, p. [488][2] Repurposing drugs as treatments for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning with sigma receptor ligands and expanding to other drugs from screening in the field, we became concerned that phospholipidosis was a shared mechanism underlying the antiviral activity of many repurposed drugs. For all of the 23 cationic amphiphilic drugs we tested, including hydroxychloroquine, azithromycin, amiodarone, and four others already in clinical trials, phospholipidosis was monotonically correlated with antiviral efficacy. Conversely, drugs active against the same targets that did not induce phospholipidosis were not antiviral. Phospholipidosis depends on the physicochemical properties of drugs and does not reflect specific target-based activities—rather, it may be considered a toxic confound in early drug discovery. Early detection of phospholipidosis could eliminate these artifacts, enabling a focus on molecules with therapeutic potential. [1]: /lookup/doi/10.1126/science.abi4708 [2]: /lookup/doi/10.1126/science.abj9488
领域	气候变化 ; 资源环境
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/335538
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Tia A. Tummino,Veronica V. Rezelj,Benoit Fischer,et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2[J]. Science,2021.
APA	Tia A. Tummino.,Veronica V. Rezelj.,Benoit Fischer.,Audrey Fischer.,Matthew J. O’Meara.,...&Brian K. Shoichet.(2021).Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.Science.
MLA	Tia A. Tummino,et al."Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2".Science (2021).